Compare VELO & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | COEP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 100.4M |
| IPO Year | N/A | N/A |
| Metric | VELO | COEP |
|---|---|---|
| Price | $18.13 | $14.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 55.7K |
| Earning Date | 02-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,158,000.00 | $500,996.00 |
| Revenue This Year | $11.94 | N/A |
| Revenue Next Year | $56.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.44 | N/A |
| 52 Week Low | $1.43 | $6.26 |
| 52 Week High | $23.84 | $21.41 |
| Indicator | VELO | COEP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.45 |
| Support Level | N/A | $11.25 |
| Resistance Level | N/A | $14.69 |
| Average True Range (ATR) | 0.00 | 1.02 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 66.94 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.